CRGX stock icon

CARGO Therapeutics
CRGX

$15.57
4.5%
 

About: Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Employees: 123

0
Funds holding %
of 6,702 funds
Analysts bullish %
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

250% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 6

200% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 10

44% more funds holding

Funds holding: 45 [Q4 2023] → 65 (+20) [Q1 2024]

7.57% more ownership

Funds ownership: 84.88% [Q4 2023] → 92.45% (+7.57%) [Q1 2024]

0% more capital invested

Capital invested by funds: $809M [Q4 2023] → $812M (+$2.77M) [Q1 2024]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 2 (-1) [Q1 2024]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$32
106%
upside
Avg. target
$32
106%
upside
High target
$32
106%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Truist Securities
Asthika Goonewardene
106%upside
$32
Buy
Reiterated
16 May 2024
Jefferies
Michael Yee
106%upside
$32
Buy
Maintained
22 Mar 2024

Financial journalist opinion

Based on 4 articles about CRGX published over the past 30 days